Stephanie Mowdy, APRN
Acute Care · Ada, OKNPI 1316178262
Payments from drug & device makers
What this record shows
Mimedx Group, Inc. accounts for 82.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $1,775 and has fallen 83.4% since, to $295 in 2025.
Across 71 payments — averaging $32.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$2K
- Next Science LLC$152
- Solventum Corporation$35
- Reprise Biomedical, Inc.$34
- KCI USA, Inc.$25
- Organogenesis Inc.$23
- plus $126 from 8 others
What the payments were for
- Travel & lodging$1,18251%
- Food & beverage$1,11849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 46 | $1,904 |
| Next Science LLC | 12 | $152 |
| Solventum Corporation | 1 | $35 |
| Reprise Biomedical, Inc. | 2 | $34 |
| KCI USA, Inc. | 1 | $25 |
| Organogenesis Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Hartmann USA, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $17 |
| AstraZeneca | 1 | $14 |
| AbbVie | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Novo Nordisk | 1 | $12 |
How this compares
$2,300 in reported general payments places this provider in the 75th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 104 | $2,048 |
| Clindamycin Hcl | 32 | $870 |
| Ciclopirox | 16 | $723 |
| Gabapentin | 52 | $629 |
| Ciprofloxacin Hcl | 43 | $388 |
| Pentoxifylline | 11 | $286 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $277 |
| Levofloxacin | 15 | $256 |
| Fluconazole | 20 | $236 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $214 |
| Prednisone | 21 | $122 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $107 |
| Tramadol Hcl | 19 | $26 |
Paid to pharmacies, not to this prescriber.
Other acute care in Ada
- Karen GregoryOklahoma City$68K
- Pavel BuzadzhiTulsa$26K
- Jerrie MoralesTulsa$15K
- Lisa ArmstrongTulsa$14K
- Ganna StarkeyTulsa$14K
- Katrina PyleOklahoma City$13K
- Deborah PeterOklahoma City$12K
- Jasmine ThompsonTulsa$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.